Content area

Abstract

Purpose of Review

We review recent advances in the treatment of treatment-resistant depression (TRD), a disorder with very limited treatment options until recently. We examine advances in psychotherapeutic, psychopharmacologic, and interventional psychiatry approaches to treatment of TRD. We also highlight various definitions of TRD in recent scientific literature.

Recent Findings

Recent evidence suggests some forms of psychotherapy can be effective as adjunctive treatments for TRD, but not as monotherapies alone. Little recent evidence supports the use of adjunctive non-antidepressant pharmacotherapies such as buprenorphine and antipsychotics for the treatment of TRD; side effects and increased medication discontinuation rates may outweigh the benefits of these adjunctive pharmacotherapies. Finally, a wealth of recent evidence supports the use of interventional approaches such as electroconvulsive therapy, ketamine/esketamine, and transcranial magnetic stimulation for TRD.

Summary

Recent advances in our understanding of how to treat TRD have largely expanded our knowledge of best practices in, and efficacy of, interventional psychiatric approaches. Recent research has used a variety of TRD definitions for study inclusion criteria; research on TRD should adhere to inclusion criteria based on internationally defined guidelines for more meaningfully generalizable results.

Details

Title
Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023
Author
Havlik, John L. 1 ; Wahid, Syed 2 ; Teopiz, Kayla M. 3 ; McIntyre, Roger S. 4 ; Krystal, John H. 5 ; Rhee, Taeho Greg 6 

 Yale University School of Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 The University of Chicago, Chicago, USA (GRID:grid.170205.1) (ISNI:0000 0004 1936 7822) 
 Brain and Cognition Discovery Foundation, Toronto, Canada (GRID:grid.490755.a) 
 Brain and Cognition Discovery Foundation, Toronto, Canada (GRID:grid.490755.a); University of Toronto, Department of Psychiatry, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Pharmacology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
 Yale University School of Medicine, Department of Psychiatry, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710) 
 Yale University School of Medicine, Department of Psychiatry, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); University of Connecticut, Department of Public Health Sciences, Farmington, USA (GRID:grid.63054.34) (ISNI:0000 0001 0860 4915) 
Pages
176-213
Publication year
2024
Publication date
Apr 2024
Publisher
Springer Nature B.V.
ISSN
15233812
e-ISSN
15351645
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3013898527
Copyright
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.